Clinical efficacy of recombinant human latrophilin 3 antibody in the treatment of pediatric asthma

  • Authors:
    • Maohua Liu
    • Jingxiu Zhang
    • Chengjun Liu
  • View Affiliations

  • Published online on: October 25, 2017     https://doi.org/10.3892/etm.2017.5376
  • Pages:539-547
Metrics: HTML 0 views | PDF 0 views
0

Abstract

Pediatric asthma is a chronic pulmonary inflammatory disease featuring hypersecretion of mucus and inflammation in the airway, resulting in dysfunction of the airway smooth muscle. Previous evidence demonstrated that latrophilins, a novel family of receptors, present a beneficial effect on airway smooth muscle cells. In the present study, the therapeutic effects of recombinant human latrophilin 3 (rhLPHN3) antibody (Ab) in patients with pediatric asthma were investigated, and the molecular mechanism underlying the function of LPHN3 in the treatment of asthma in clinical practice was examined. A total of 342 pediatric asthma cases were recruited and randomly divided into three groups, receiving treatment with rhLPHN3 Ab (n=134), salbutamol (n=108) or montelukast (n=100) by nasal aerosolization. Each group received the respective clinically tested dose for 16 weeks. Inflammatory factors interleukin (IL)‑10, IL‑17, IL‑4, matrix metallopeptidase‑9 (MMP‑9), interferon‑γ (IFN‑γ) and transforming growth factor‑β (TGF‑β) levels in peripheral blood mononuclear cells were analyzed prior to and post treatment. The clinical outcomes revealed that pathological alterations were significantly improved following treatment with rhLPHN3 Ab for patients with pediatric asthma when compared with those receiving salbutamol and montelukast. It was also observed that rhLPHN3 Ab downregulated the plasma concentration levels of IL‑10, IL‑17, IL‑4 and MMP‑9, and upregulated IFN‑γ and TGF‑β levels in the three groups. In addition, clinical data demonstrated that rhLPHN3 Ab significantly promoted E‑selectin and mucin 5AC expression, as well as improved the activation of nuclear factor (NF)‑κB p65 DNA binding activity and the phosphorylation levels of protein kinase A. Furthermore, rhLPHN3 Ab markedly improved adhesion and proliferation of airway smooth muscle cells, which led to promotion of the contraction of these cells.In conclusion, these clinical data suggest that rhLPHN3 Ab serves an important role in the inhibition of inflammatory mediators through downregulation of NF‑κB signaling pathway, which contributes to airway remodeling and bronchodilation in patients with pediatric asthma.

Related Articles

Journal Cover

January 2018
Volume 15 Issue 1

Print ISSN: 1792-0981
Online ISSN:1792-1015

2016 Impact Factor: 1.261
Ranked #50/128 Medicine Research and Experimental
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Liu, M., Zhang, J., & Liu, C. (2018). Clinical efficacy of recombinant human latrophilin 3 antibody in the treatment of pediatric asthma. Experimental and Therapeutic Medicine, 15, 539-547. https://doi.org/10.3892/etm.2017.5376
MLA
Liu, M., Zhang, J., Liu, C."Clinical efficacy of recombinant human latrophilin 3 antibody in the treatment of pediatric asthma". Experimental and Therapeutic Medicine 15.1 (2018): 539-547.
Chicago
Liu, M., Zhang, J., Liu, C."Clinical efficacy of recombinant human latrophilin 3 antibody in the treatment of pediatric asthma". Experimental and Therapeutic Medicine 15, no. 1 (2018): 539-547. https://doi.org/10.3892/etm.2017.5376